Growth Metrics

Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) (2016 - 2025)

Pacific Biosciences Of California has reported EPS (Weighted Average and Diluted) over the past 10 years, most recently at -$0.13 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.13 for Q4 2025, up 70.45% from a year ago — trailing twelve months through Dec 2025 was -$1.84 (down 15.72% YoY), and the annual figure for FY2025 was -$1.82, down 14.47%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.13 at Pacific Biosciences Of California, roughly flat from -$0.13 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PACB hit a ceiling of -$0.13 in Q3 2025 and a floor of -$1.44 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.32 (2022), compared with a mean of -$0.37.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 4600.0% in 2021 and later surged 78.12% in 2025.
  • Pacific Biosciences Of California's EPS (Weighted Average and Diluted) stood at -$0.33 in 2021, then decreased by 12.12% to -$0.37 in 2022, then increased by 16.22% to -$0.31 in 2023, then plummeted by 41.94% to -$0.44 in 2024, then surged by 70.45% to -$0.13 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.13 (Q4 2025), -$0.13 (Q3 2025), and -$0.14 (Q2 2025) per Business Quant data.